Holen Sie sich die Stockscreener-App
9.91
0.10%
-0.010
Exozymes Inc Aktie (EXOZ) Neueste Nachrichten
Number of shareholders of eXoZymes Inc. – NASDAQ:EXOZ - TradingView
EXOZ Technical Analysis | Trend, Signals & Chart Patterns | EXOZYMES INC (NASDAQ:EXOZ) - ChartMill
EXOZYMES INC. 1Q 2026: Revenue $0 Net income $(2.37M) — 10-Q Summary - TradingView
EXoZymes, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
eXoZymes (NASDAQ: EXOZ) Q1 2026 loss deepens amid cash burn, planned raise - Stock Titan
TradingKey - TradingKey
eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program - ACCESS Newswire
eXoZymes Prepares Investor Presentation for Proposed Public Offering - TipRanks
eXoZymes (EXOZ) files investor presentation for proposed securities offering - Stock Titan
Video Interview: Successful Pilot-Scale Run with Cayman Chemical Validates eXoZymes’ Technology and Scalability - The National Law Review
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Dr - The National Law Review
eXoZymes (NASDAQ:EXOZ) Shares Down 0.4%Should You Sell? - MarketBeat
Damien Alan Perriman Net Worth (2026) - GuruFocus
eXoZymes Advances Toward Planned Securities Offering Preparation - The Globe and Mail
Insider Sell: Tyler Korman Sells 1,500 Shares of EXoZymes Inc (E - GuruFocus
eXoZymes (EXOZ) files investor presentation tied to proposed securities offering - Stock Titan
eXoZymes CCO discusses NCTx spinout on podcast By Investing.com - Investing.com Australia
Exozymes (EXOZ) CSO logs small April open-market stock sales - Stock Titan
eXoZymes CCO discusses NCTx spinout on podcast - Investing.com
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast - ACCESS Newswire
Why eXoZymes spun out NCTx to take NCT down the supplement path - Stock Titan
Surprises Report: What are eXoZymes Incs recent SEC filings showing2026 Support & Resistance & Verified Technical Trade Signals - baoquankhu1.vn
Exozymes Incannounces common stock offeringSEC filing - marketscreener.com
eXoZymes (NASDAQ: EXOZ) files prospectus for common stock offering with affiliated underwriter - Stock Titan
Pullback Watch: Is eXoZymes Inc backed by strong institutional buyingPortfolio Update Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
EXOZYMES (EXOZ) CCO awarded 146,437 options and 62,759 restricted shares - Stock Titan
EXOZYMES (NASDAQ: EXOZ) Chief Commercial Officer files initial Form 3 - Stock Titan
Insider Trends: Can eXoZymes Inc sustain earnings growthMarket Sentiment Review & Growth Oriented Trading Recommendations - baoquankhu1.vn
Latest EXOZ ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
EXOZ Technical Analysis & ETF Price Forecast - Intellectia AI
EXOZYMES (NASDAQ: EXOZ) CCO receives 8,887-share stock grant - Stock Titan
EXOZYMES (EXOZ) VP awarded 3,999 common shares as stock grant - Stock Titan
[Form 4] EXOZYMES INC. Insider Trading Activity - Stock Titan
Exozymes (EXOZ) CSO receives 5,332-share stock award - Stock Titan
Bond Watch: Is eXoZymes Inc a speculative investment2026 Price Swings & Detailed Earnings Play Strategies - baoquankhu1.vn
Does eXoZymes Inc stock have upside surprise potential2026 Fundamental Recap & Weekly Market Pulse Updates - baoquankhu1.vn
EXOZ PE Ratio & Valuation, Is EXOZ Overvalued - Intellectia AI
Nasdaq Moves: Is eXoZymes Inc forming a bullish divergenceShare Buyback & High Accuracy Buy Signal Tips - baoquankhu1.vn
EXoZymes Inc (EXOZ) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
eXoZymes Provides Fourth Quarter and Full Year 2025 Update - Bitget
EXOZ: NCT achieved kilo-scale production and tech transfer, with a financing round in progress - TradingView — Track All Markets
eXoZymes Inc's Capital Raise Delays and NCT Timeline Shifts Highlight Strategic Contradictions - Bitget
eXoZymes Q4 Earnings Call Highlights - MarketBeat
EXOZ: Pilot-scale NCT production achieved; financing round underway to support 2027 commercial launch - TradingView
Earnings call transcript: eXoZymes Q4 2025 results show strategic focus - Investing.com
eXoZymes ends 2025 with $3.04M cash as financing round nears - Stock Titan
eXoZymes Updates Investor Presentation for NCTx Business - TipRanks
eXoZymes (NASDAQ: EXOZ) files updated NCTx investor presentation - Stock Titan
eXoZymes Q4 2025 Earnings Call Transcript - MarketBeat
eXoZymes (NASDAQ: EXOZ) outlines exozyme platform and NCT plans - Stock Titan
EXoZymes, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
EXoZymes, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Institution Moves: Can eXoZymes Inc sustain earnings growth2026 Geopolitical Influence & Technical Pattern Recognition Alerts - baoquankhu1.vn
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):